For this reason, and in consideration of the significant efficacy of both rosiglitazone and pioglitazone as inhibitors of oral carcinogenesis, PPARγ remains a potentially valuable molecular target for cancer chemoprevention in the oral cavity and other sites [22,28]. The gene discussed is PPARG; the disease is cancer.